On Nov. 27, 2023, the CDCﾒs Tuberculosis Trials Consortium (TBTC) announced that it had launched an international clinical trial, Combination Regimens for Shortening Tuberculosis Treatment, or CRUSH-TB. This exciting new trial aims to identify new combinations of drugs to provide additional options to shorten the treatment of tuberculosis (TB) disease.

The trial compares the effectiveness and safety of new 4-month bedaquiline, moxifloxacin, and pyrazinamide-based regimens to the standard of care 6-month regimen among patients with drug-susceptible pulmonary TB disease.